Definium Therapeutics, Inc. (DFTX)
DFTXNASDAQ-GS Medicinal Chemicals and Botanical Products
$33.00
+0.7500 (+2.33%) today
At the close, Nov 12, 4:00 PM ET. Pre-market $32.80 -0.61%
- Market cap
- $4.49bn
- P/E
- –
- EPS, last 4 quarters
- $-3.06
- Dividend yield
- –
- Day range
- –
- 52-week range
- $10.46 to $49.70
- Average volume
- –
- Previous close
- $32.25
Analysts
15 coveringBuy15 buy, 0 hold, 0 sell
Targets a year out average $74.31, +125.2% from here
Earnings
next estimate $-0.5100Next report
Dec 2025
0.0%
Mar 2026
-51.1%
Jun 2026
-161.8%
Sep 2026
+16.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$47.58m | -$59.22m | -$75.08m | -$72.28m |
| Net income | -$50.44m | -$77.10m | -$158.99m | -$50.96m |
News
8 latest- Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 StudiesMarketBeat · 2 days ago
- Definium Therapeutics Reports Third Quarter 2026 Financial ResultsFintel · 3 days ago
- Definium (DFTX) Q3 2026 Earnings Call TranscriptThe Motley Fool · 3 days ago
- What Definium Therapeutics (DFTX) Said on Its Q3 Earnings CallMarketBeat · 4 days ago
- Definium Therapeutics Consensus Price Target Raised 12.21% to $73.32Fintel · Oct 2, 2026
- Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and DepressionMarketBeat · Sep 24, 2026
- Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety StudyMarketBeat · Sep 19, 2026
- Stocks Settle Lower as AI Slowdown Fears Weigh on ChipmakersBarchart · Sep 15, 2026
The company
The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today's mental health care crisis and enable a healthier future.
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- definiumtx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.